Tigress Financial initiated coverage of IFF (IFF) with a Buy rating and $105 price target IFF is strategically positioned for long-term growth by capitalizing on the rising consumer demand for health-oriented and functional products, targeted investments, and a broad product portfolio, combined with its ongoing focus on R&D-driven opportunities and balance sheet and product portfolio optimization, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFF:
- Positive Outlook for IFF: Buy Rating Supported by Stability and Growth Potential
- Icahn boosts stakes in CVR Partners, JetBlue, Illumina
- IFF price target lowered to $98 from $100 at Morgan Stanley
- Strong Growth Potential and Attractive Valuation Make International Flavors & Fragrances a Compelling Investment
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls